Informations sur le produit
- L-Cys(Bzl)-pNA
- (2R)-2-Amino-3-benzylsulfanyl-N-(4-nitrophenyl)propanamide
- (2R)-2-Amino-N-(4-nitrophenyl)-3-[(phenylmethyl)thio]propanamide
- H-Cys(Bzl)-Pna
- L-2-Amino-3-(benzylthio)-4'-nitropropionanilide
- Propanamide, 2-amino-N-(4-nitrophenyl)-3-((phenylmethyl)thio)-, (2R)-
- Propanamide, 2-amino-N-(4-nitrophenyl)-3-[(phenylmethyl)thio]-, (R)-
- Propionanilide, 2-amino-3-(benzylthio)-4′-nitro-, (R)-
- S-Benzyl-<span class="text-smallcaps">L</span>-cysteine 4-nitroanilide
- S-Benzyl-<span class="text-smallcaps">L</span>-cysteine-p-nitroanilide
- Voir d'autres synonymes
- S-Benzyl-L-cysteine-4'-nitroanilide
S-Benzyl-L-cysteine 4-nitroanilide (SBCNA) is a synthetic compound that belongs to the group of arylamidase inhibitors. It is used in the treatment of asthma, allergic rhinitis, and chronic obstructive pulmonary disease. SBCNA inhibits leukotriene D4 synthesis by binding to the enzyme phospholipase A2. It also has been shown to inhibit prostaglandin synthesis in human platelets and erythrocytes. Clinical trials have shown that SBCNAs are effective against women with bronchial asthma, with an increased reaction rate in this population compared to men. SBCNA has also been shown to be active against both normal and neoplastic tissues, as well as inhibiting the release of acrosomal vesicles from rat spermatozoa at concentrations of 1 μM or higher.